Global Health Limited

rs,

Ref:- GHL/2023-24/EXCH/38 The General Manager Dept. of Corporate Services BSE Limited, P J Towers, Dalal Street, Mumbai - 400 001 The Manager Listing Department National Stock Exchange of India

INR 7,945 million

formance driven by growth in patient footfalls and improved realizations e m o c n I l a t o T INR 7,945 million Q1 FY23 6,265 million 26.8% d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1%

6,265 million

n patient footfalls and improved realizations e m o c n I l a t o T INR 7,945 million Q1 FY23 6,265 million 26.8% d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million

26.8%

falls and improved realizations e m o c n I l a t o T INR 7,945 million Q1 FY23 6,265 million 26.8% d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million Margin

INR 1,993 million

I l a t o T INR 7,945 million Q1 FY23 6,265 million 26.8% d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020

25.1%

illion Q1 FY23 6,265 million 26.8% d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin

1,416 million

6,265 million 26.8% d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin: 12.8% Q1 FY23 587 mn

22.6%

d n a A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin: 12.8% Q1 FY23 587 mn Margin: 9.4%

40.7%

A D T I B E i % s n g r a M INR 1,993 million Margin: 25.1% Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin: 12.8% Q1 FY23 587 mn Margin: 9.4% 73.7%

INR 1,020 million

93 million Margin: 25.1% Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin: 12.8% Q1 FY23 587 mn Margin: 9.4% 73.7% d e B d e p u c c O i s y a D 117,501 ) R N

12.8%

Q1 FY23 1,416 million Margin: 22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin: 12.8% Q1 FY23 587 mn Margin: 9.4% 73.7% d e B d e p u c c O i s y a D 117,501 ) R N I ( 63,148

9.4%

22.6% 40.7% d n a T A P i % s n g r a M INR 1,020 million Margin: 12.8% Q1 FY23 587 mn Margin: 9.4% 73.7% d e B d e p u c c O i s y a D 117,501 ) R N I ( 63,148 Q1 FY23 101,099 16.2% * B

“~60% of the planned bed addition will be at existing hospitals; resulting in lower capex / bed • Floor area of 100K+ sq.”

Notes

1

Notes

1. Revenue from healthcare services excludes pharmacy revenue and other income 2. Revenue breakdowns are provided as per internal MIS at the Company’s consolidated level 3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery 11 Growth seen in both mature and new hospitals New hospitals continue to deliver strong growth Matured hospitals - Over 6 years Developing hospitals - Less than 6 years Total Income (INR million) EBITDA (INR million and margin %) Total Income (INR million) EBITDA (INR million and margin %) +20.2% 5,778 4,806 +31.1% 1,426 1,087 +56.5% 2,297 1,468 +117.6% 720 331 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 22.6% 24.7% 22.6% 31.4% Occupied Bed Days ARPOB* (INR) Occupied Bed Days ARPOB* (INR) +4.9% 77,011 80,817 +9.7% 59,291 65,067 +52.3% +2.1% 36,684 58,004 59,227 24,088 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 59% 60% 61% 54% *ARPOB is calculated on Hospital R